ST Pharm Co.,Ltd.

A237690

KR7237690003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
91,000 ^KRW	-0.22%		-3.29%	+34.22%

2023	ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2021	ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility	CI

ST Pharm Co.,Ltd. acquired 70% stake in AnaPath GmbH.

November 26, 2019

ST Pharm Co.,Ltd. (KOSDAQ:A237690) acquired 70% stake in AnaPath GmbH on November 27, 2019. In a related transaction, AnaPath GmbH acquired Envigo CRS. Toby Grainger of CMS Holborn Asia, Stefan Brunnschweiler of CMS von Erlach Poncet and Jose Buqueras, Jorge Prada and Pedro Ferreras of CMS Albiñana & Suárez de Lezo, S.L.P. acted as legal advisors to ST Pharm Co.,Ltd.. ST Pharm Co.,Ltd. (KOSDAQ:A237690) completed the acquisition of 70% stake in AnaPath GmbH on November 27, 2019.

Latest news about ST Pharm Co.,Ltd.

ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/03/23	CI
ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility	29/11/21	CI
Samsung Biologics : S.Korea pledges nearly $2 bln to become major COVID-19 vaccine producer	05/08/21	RE
Market Chatter: ST Pharm to Launch mRNA-based COVID-19 Vaccine in 2022	24/06/21	MT
ST Pharm Co.,Ltd. announced that it has received KRW 110 billion in funding	10/12/20	CI
ST Pharm Co.,Ltd. announced that it expects to receive KRW 110 billion in funding	06/12/20	CI
Avidity Biosciences, Inc. announced that it has received $78.999943 million in funding from Alethea Capital Management, LLC, Alexandria Venture Investments, LLC, Takeda Ventures, Inc., CureDuchenne Ventures LLC, ST Pharm Co.,Ltd.	30/01/20	CI
ST Pharm Co.,Ltd. acquired 70% stake in AnaPath GmbH.	26/11/19	CI
Avidity Biosciences, Inc. announced that it expects to receive $76.699946 million in funding from Alethea Capital Management, LLC, Alexandria Venture Investments, LLC, Takeda Ventures, Inc., CureDuchenne Ventures LLC, ST Pharm Co.,Ltd.	07/11/19	CI
Dong-A Socio Holdings Co. Ltd. cancelled the acquisition of an additional stake in ST Pharm Co. Ltd..	22/08/17	CI
Dong-A Socio Holdings Co. Ltd. cancelled the acquisition of additional 10% stake in ST Pharm Co. Ltd. from Dong-A ST Co., Ltd..	23/12/16	CI
ST Pharm Co.,Ltd. cancelled the acquisition of Banwol Factory from Dong-A ST Co., Ltd..	28/10/16	CI
ST Pharm Co. Ltd.(KOSDAQ:A237690) added to S&P Global BMI Index	19/09/16	CI
Dong-A Socio Holdings Co. Ltd. made a tender offer to acquire an additional stake in ST Pharm Co. Ltd. for approximately KRW 170 million.	22/08/16	CI
ST Pharm Co. Ltd. has completed an IPO in the amount of KRW 135.26 billion.	22/06/16	CI
ST Pharm Co. Ltd. has filed an IPO.	16/03/16	CI
Dong-A Socio Holdings Co. Ltd. agreed to acquire additional 10% stake in ST Pharm Co. Ltd. from Dong-A ST Co., Ltd. for KRW 25.9 billion.	23/12/15	CI
ST Pharm Co.,Ltd. agreed to acquire Banwol Factory from Dong-A ST Co., Ltd. for KRW 51 billion.	28/10/15	CI
Dong-A Socio Holdings Co. Ltd. completed the acquisition of additional 2.7% stake in Dong-A ST Co.,Ltd from Jung-Seok Kang, ST Pharm Co. Ltd., Sangju Academy and others.	27/10/14	CI
Dong-A Socio Holdings Co. Ltd. made an offer to acquire additional 2.7% stake in Dong-A ST Co.,Ltd from Jung-Seok Kang, ST Pharm Co. Ltd., Sangju Academy and others for KRW 19.9 billion.	02/09/14	CI

Chart ST Pharm Co.,Ltd.

Duration

Period

More charts

Company Profile

STPharm Co.,Ltd. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The Company's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

03/06/2024 - Kiwoom Innovative Growth Corporate Day

More about the company

Income Statement Evolution

More financial data

Ratings for ST Pharm Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

91,000 KRW

Average target price

105,000 KRW

Spread / Average Target

+15.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ST PHARM CO.,LTD.	+34.22%	1.27B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals

ST Pharm Co.,Ltd.

Equities

A237690

KR7237690003

Pharmaceuticals

ST Pharm Co.,Ltd. acquired 70% stake in AnaPath GmbH.

Latest news about ST Pharm Co.,Ltd.

Chart ST Pharm Co.,Ltd.

Company Profile

Income Statement Evolution

Ratings for ST Pharm Co.,Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals